BridgeBio Pharma, Inc.

Contributing Author

Recent Articles by BridgeBio Pharma, Inc.

Jun-02	BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 BBIO GlobeNewswire
May-20	Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM BBIO GlobeNewswire
May-19	Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study BBIO GlobeNewswire
May-14	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BBIO GlobeNewswire
May-13	First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study BBIO GlobeNewswire
May-12	BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC BBIO GlobeNewswire
May-07	BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 BBIO GlobeNewswire